Not yet recruiting

Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma

By April 24, 2017 No Comments


Mesothelioma|Pleural Mesothelioma

Estimated Enrollment: 55

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment

Study ID Numbers: PrE0505|ESR-15-10792

Study First Received: September 8, 2016

Last Updated: March 3, 2017

Estimated Primary Completion Date: August 2020


Primary Outcome Measures:

Overall Survival (OS)|Number of participants with treatment-related adverse events as assessed by CTCAE v4.03|Progression-Free Survival (PFS)|Time to Progression (TTP) on Durvalumab|Objective Response Rate (ORR)

Sponsors and Collaborators:

PrECOG, LLC.|AstraZeneca

Website Link:

Leave a Reply

Call Now ButtonCall Now